|
RPP30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.79363248884601E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.35820030169975E-10 |
| Normal-vs-Stage2 |
2.50329978968011E-10 |
| Normal-vs-Stage3 |
7.11450000023817E-08 |
| Normal-vs-Stage4 |
9.58749968305028E-10 |
| Stage1-vs-Stage2 |
1.110010E-02 |
| Stage1-vs-Stage3 |
9.942800E-01 |
| Stage1-vs-Stage4 |
1.724780E-01 |
| Stage2-vs-Stage3 |
3.387700E-02 |
| Stage2-vs-Stage4 |
3.216600E-01 |
| Stage3-vs-Stage4 |
2.443800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.18870024934381E-10 |
| Normal-vs-AfricanAmerican |
1.55889999997605E-06 |
| Normal-vs-Asian |
4.2371000000041E-05 |
| Caucasian-vs-AfricanAmerican |
7.541400E-01 |
| Caucasian-vs-Asian |
2.126200E-01 |
| AfricanAmerican-vs-Asian |
2.514400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.24230004061587E-09 |
| Normal-vs-Female |
1.59510182839995E-11 |
| Male-vs-Female |
3.370400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.81899995066459E-09 |
| Normal-vs-Age(41-60Yrs) |
1.46129996991817E-10 |
| Normal-vs-Age(61-80Yrs) |
1.5817003262697E-10 |
| Normal-vs-Age(81-100Yrs) |
4.282200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.489440E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.995500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.141600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.933400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.300600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.718000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.687600E-01 |
| Classical-VS-Follicular |
1.02339999996648E-06 |
| Classical-VS-Other |
7.645600E-01 |
| Classical-VS-Normal |
4.79200001901603E-09 |
| Tall-VS-Follicular |
1.379630E-04 |
| Tall-VS-Other |
4.446600E-01 |
| Tall-VS-Normal |
1.181090E-03 |
| Follicular-VS-Other |
2.505400E-01 |
| Follicular-VS-Normal |
2.1449508835758E-12 |
| Other-VS-Normal |
1.405930E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.86115575676149E-12 |
| Normal-vs-N1 |
8.4054000004663E-07 |
| N0-vs-N1 |
1.237650E-01 |
|
|
